Active substance
Results for the substance cobimetinib
1 result
About this active substance
Cobimetinib is a MEK kinase inhibitor used for the treatment of metastatic or unresectable melanoma with a BRAF V600 mutation. It works by inhibiting the MAPK signaling pathway, reducing tumor cell growth and proliferation.
The medication is taken orally, as directed by a doctor, usually once daily in treatment cycles. It is important for patients to undergo regular check-ups to monitor the therapy's effectiveness and side effects.
Patients should be aware of potential side effects, such as nausea, diarrhea, or photosensitivity. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, and photosensitivity. In rare cases, severe reactions such as heart failure, bleeding, or liver dysfunction may occur. Patients should be informed of these risks before use.
The medication is taken orally, as directed by a doctor, usually once daily in treatment cycles. It is important for patients to undergo regular check-ups to monitor the therapy's effectiveness and side effects.
Patients should be aware of potential side effects, such as nausea, diarrhea, or photosensitivity. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, and photosensitivity. In rare cases, severe reactions such as heart failure, bleeding, or liver dysfunction may occur. Patients should be informed of these risks before use.